AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
holding Jemperli and future imsidolimab royalties, and a development-focused biopharma company housing ANB033, ANB101, rosnilimab, cash and employees. Jemperli is the primary value driver (exited 2025 at well north of $1.4 billion run-rate and growing mid-teens QoQ), and partner Vanda's BLA for imsidolimab has a PDUFA in December , which could create a second commercial royalty asset. AnaptysBio began the year with about $310 million cash; management says the royalty business needs roughly $20 million runway, while the biopharma side would require ~ $100 million to fund ANB033 through phase 2 into late 2027 or ~ $200 million to extend into late 2028, with ANB033 readouts expected by Q4 and rosnilimab showing encouraging disease-modifying signals in RA. Interested in AnaptysBio, Inc.? Here are five stocks we like better. Argenx's 28% Surge & Promising Product Propel Investor Confidence AnaptysBio (NASDAQ:ANAB) outlined plans at TD Cowen's 46th Annual Healthcare Conference to
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.MarketBeat
- Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/13/26 - Form 4
- ANAB's page on the SEC website